Wakamoto Pharmaceutical Co (TSE:4512) Total Liabilities: 円4,491 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4512 Wakamoto Pharmaceutical Co Ltd TSE:4512
63 GF Score
Price 円278.00
GF Value 円319.14
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Wakamoto Pharmaceutical Co Total Liabilities?

Wakamoto Pharmaceutical Co TSE:4512 63 Total Liabilities is 円4,491 Mil as of Mar. 2026. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.14 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Wakamoto Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 was 円4,491 Mil.

Wakamoto Pharmaceutical Co's quarterly Total Liabilities declined from Mar. 2025 (円3,392.36 Mil) to Sep. 2025 (円3,289.49 Mil) but then increased from Sep. 2025 (円3,289.49 Mil) to Mar. 2026 (円4,491.03 Mil).

Wakamoto Pharmaceutical Co's annual Total Liabilities declined from Mar. 2024 (円3,394.98 Mil) to Mar. 2025 (円3,392.36 Mil) but then increased from Mar. 2025 (円3,392.36 Mil) to Mar. 2026 (円4,491.03 Mil).

Wakamoto Pharmaceutical Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Wakamoto Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Total Liabilities Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,472.63 3,804.89 3,394.98 3,392.36 4,491.03

Wakamoto Pharmaceutical Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,394.98 3,310.23 3,392.36 3,289.49 4,491.03
TSE:4512
63GF Score
Wakamoto Pharmaceutical Co Ltd TSE:4512
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wakamoto Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Wakamoto Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2781.298+(261.54+440.316
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+1007.874+0)
=4,491

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=16499.607-12008.579
=4,491

Wakamoto Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2781.298+(261.54+440.316
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+1007.874+0)
=4,491

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=16499.607-12008.579
=4,491

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of 円4,491 Mil mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Total Liabilities of 円4,491 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Total Liabilities too high?
Wakamoto Pharmaceutical Co's current Total Liabilities is 円4,491 Mil. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Total Liabilities compare to ZTS and UTHR?
Wakamoto Pharmaceutical Co's Total Liabilities of 円4,491 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Total Liabilities is 円4,491 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.14, compared to a current price of 円278.00 — trading 12.9% below its estimated fair value. The current Total Liabilities is 円4,491 Mil. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Total Liabilities is 円4,491 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?

Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円278.00 is trading 12.9% below its estimated GF Value™ of 円319.14. GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4512:

  • Total Liabilities: 円4,491 Mil
  • GF Value™: 円319.14 vs. price of 円278.00 (12.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wakamoto Pharmaceutical Co Business Description

Address 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score

Get the complete analysis for TSE:4512

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円278.00
Price
円319.14
GF Value